Thymalin
Human observationalAlso known as: Thymus peptide extract
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A thymus-derived peptide preparation used clinically in Russia and some neighbouring countries as an immunomodulator. Independent evidence outside that setting is limited.
Mechanism
Proposed to help normalise T-cell function and immune balance; mechanism is not firmly established in modern independent research.
Evidence
Some regional clinical history; robust independent RCT evidence and international approval are lacking.
Community-reported information
Where used clinically, dosed by a clinician. Outside that, anecdotal; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Short.
Storage
Refrigerate.
Commonly reported side effects
- Generally reported as well tolerated
- Injection-site reactions
Legal status by region
- USNot FDA-approved for human use.
- GBNot licensed for general use.
Legal status changes over time; verify locally before relying on this.